FDA Building Effective Fast Track for US Medtechs While Other Countries Starting to Show Delays

Lisa Wipperman Heine, COO of Mitralign, says the FDA is making quicker work of review times. But the same might not be said for other countries where Medtechs once had a faster time to market. In this interview at the offices of Fox Rothschild in Minneapolis, the Medtech veteran lays out Mitralign’s success with the agency’s Early Feasibility program.